Coya Therapeutics (COYA) Common Equity (2021 - 2026)

Coya Therapeutics (COYA) has 6 years of Common Equity data on file, last reported at $49.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 46.75% year-over-year to $49.0 million; the trailing twelve-month figure through Mar 2026 stood at $49.0 million (up 46.75% YoY), and the FY2025 full-year result was $43.0 million, up 8.72% from the prior year.
• Common Equity rose to $49.0 million in Q1 2026, from $43.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $49.0 million in Q1 2026 to a low of -$8.4 million in Q4 2022.
• A 5-year average of $22.5 million and a median of $28.3 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 330.36% in 2022 and surged 1042.04% in 2023, its largest moves.
• Tracing COYA's Common Equity over 5 years: stood at -$8.4 million in 2022, then soared by 524.56% to $35.6 million in 2023, then rose by 11.06% to $39.6 million in 2024, then rose by 8.72% to $43.0 million in 2025, then grew by 13.81% to $49.0 million in 2026.
• Business Quant data shows COYA's Common Equity at $49.0 million in Q1 2026, $43.0 million in Q4 2025, and $27.3 million in Q3 2025.